Heart Corner: Innovations in Cardiovascular Science

Abdulla A. Damluji, MD, PhD
  • 4,0 (4)
  • МЕДИЦИНА
  • ЕЖЕДНЕВНО
Heart Corner: Innovations in Cardiovascular Science

Welcome to Heart Corner: Innovations in Cardiovascular Science, where we explore the latest advancements and breakthroughs in the field of cardiovascular science. This podcast discusses cutting-edge research, emerging therapies, and transformative technologies shaping the future of cardiovascular care. Join us as we discuss a wide range of topics, from groundbreaking studies on heart disease prevention and treatment to in-depth conversations on conditions like heart failure, arrhythmias, and cardiometabolic health.

  1. -1 Ч

    Episode 17: TTVR: The Future of Tricuspid Valve Replacement

    This JACC State-of-the-Art Review article provides a comprehensive overview of transcatheter tricuspid valve replacement (TTVR) for treating severe tricuspid regurgitation. The article details current TTVR systems, their mechanisms, and clinical outcomes from various studies, including a randomized controlled trial. It also explores diagnostic work-up, patient selection criteria, procedural considerations (such as managing complications like bleeding and conduction disturbances), and post-procedure care, including anticoagulation strategies. The authors offer expert recommendations based on their experience, highlighting both the potential benefits and challenges associated with TTVR. Finally, the review discusses future research directions and ongoing clinical trials aimed at expanding the understanding and application of this evolving therapy.

    29 мин.

  2. -5 ДН.

    Episode 16: Update from the American Heart Association 2024 Science Meeting from 2024

    The first trial examines the effects of tirzepatide on patients with heart failure with preserved ejection fraction and obesity. The study found that tirzepatide significantly reduced the risk of death from cardiovascular causes or worsening heart failure compared to placebo, improving health status and exercise tolerance. The second trial evaluates the use of colchicine in patients who have experienced an acute myocardial infarction, finding no significant reduction in the composite outcome of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization despite a longer treatment duration. The third trial reports on the use of spironolactone in patients who have experienced an acute myocardial infarction, with the results demonstrating no significant decrease in the risk of death from cardiovascular causes or new or worsening heart failure or the composite outcome of death from cardiovascular causes, myocardial infarction, stroke, or new or worsening heart failure. The fourth trials investigates the efficacy and safety of nex-z, a CRISPR-Cas9 gene editing therapy, for patients with transthyretin amyloidosis with cardiomyopathy. The study showed that a single dose of nex-z led to rapid and durable reductions in serum transthyretin levels with a favorable safety profile. The final trial explores the use of left atrial appendage closure as an alternative to oral anticoagulation for patients with atrial fibrillation who have undergone catheter ablation. The results suggest that left atrial appendage closure leads to a lower risk of non–procedure-related major or clinically relevant non major bleeding while being noninferior to oral anticoagulation in terms of death from any cause, stroke, or systemic embolism.

    20 мин.

  3. 14 НОЯБ.

    Episode 15: Heart Matters: Bridging the Care Gap in Cardiac Interventions for Older Women

    This medical paper examines the challenges older women face when undergoing percutaneous coronary intervention (PCI) for coronary artery disease. The authors highlight that older women are less likely to receive evidence-based treatment despite experiencing a higher risk of adverse events due to their unique physiological and anatomical differences. The paper discusses the limitations of current risk stratification tools in accurately assessing older women’s risk, and emphasizes the need for tailored procedural techniques and patient-centered care approaches. Furthermore, it calls attention to the limited research available on older women and the need for increased representation in clinical trials.

    28 мин.

  4. 10 НОЯБ.

    Episode 14: Fine-Tuning Dual Antiplatelet Therapy in Atrial Fibrillation Post-PCI – Insights from the AUGUSTUS Trial

    Summary  This study examines the effects of different antithrombotic treatments in patients with atrial fibrillation who have had an acute coronary syndrome or undergone percutaneous coronary intervention. The researchers specifically investigated whether the timing of treatment initiation, early versus late after the index event, influences the benefits and risks of dual antiplatelet therapy plus oral anticoagulation compared to a single P2Y12 inhibitor plus oral anticoagulation. The findings suggest that a short course of dual antiplatelet therapy might be beneficial early after the event, but this requires further investigation.

    14 мин.

  5. 5 НОЯБ.

    Episode #13: Age is Not a Number: Revascularization in Older Adults Aged 75 Years and Older with NSTEMI

    This study examined the effects of an invasive strategy, including coronary angiography and subsequent revascularization, compared to a conservative approach for older adults (≥75 years) experiencing non–ST‐segment–elevation acute coronary syndrome (NSTE‐ACS). The meta-analysis of nine studies indicated that invasive strategies significantly reduced the risk of death or myocardial infarction, myocardial infarction, and subsequent revascularization without increasing the risk of major bleeding. Despite limitations, the results highlight the potential benefits of invasive strategies for older adults with NSTE‐ACS, underscoring the need for future trials to further explore the nuances of geriatric conditions and to better represent the growing older adult population.

    19 мин.

  6. 3 НОЯБ.

    Episode 11: Optimizing Vascular Closure in TAVR: Insights from the ACCESS-TAVI Trial

    This is a research article describing a randomized trial comparing two different strategies for vascular access closure after transfemoral transcatheter aortic valve implantation (TF-TAVI), a procedure used to treat patients with severe aortic valve stenosis. The primary endpoint of the study was a composite of major or minor access site-related vascular complications during index hospitalization, with the study demonstrating that a combined suture-/plug-based vascular closure device (VCD) strategy was significantly superior to a suture-based VCD strategy. The study also found that the combined strategy was associated with shorter time to hemostasis and a lower rate of bleeding events compared to the suture-only approach. The researchers conclude that the combined strategy represents a promising option for vascular access closure after TF-TAVI.

    23 мин.

  7. 2 НОЯБ.

    High Stakes: Navigating Cardiogenic Shock, AKI, and Survival with mAFP in STEMI Patients

    This research article investigates the impact of using a microaxial flow pump (mAFP) on renal outcomes in patients experiencing cardiogenic shock (CS) due to ST-segment elevation myocardial infarction (STEMI). The study, a secondary analysis of the DanGer Shock trial, found that mAFP use was associated with higher rates of acute kidney injury (AKI) and renal replacement therapy (RRT), despite leading to a lower mortality rate at 180 days. The authors identify various predictors of AKI in both treatment groups, including shock severity, bleeding events, and device-related complications specific to the mAFP group, such as suction events and high pump speeds. The article concludes that while mAFP use presents a risk of AKI and RRT, the mortality benefit associated with its use remains significant, and further research should focus on minimizing the risks of device-related complications.

    18 мин.

  8. 1 НОЯБ.

    IV vs. IO: The Best Route to Survival in Cardiac Arrest?

    This medical research paper examines the effectiveness of intraosseous-first versus intravenous-first vascular access strategies in patients experiencing out-of-hospital cardiac arrest. The study, conducted in the United Kingdom, involved a randomized trial with over 6,000 participants. The primary outcome of the study was 30-day survival, with other outcomes including return of spontaneous circulation and neurologic function. The researchers found no significant difference in 30-day survival between the two groups, suggesting that an intraosseous-first strategy does not improve outcomes compared to an intravenous-first strategy. The study also explored potential explanations for the observed lack of difference and discussed limitations of the study, including underpowering and the inability to blind participants to their treatment group.

    12 мин.
См. все (17)

4
из 5
Оценок: 4

Об этом подкасте

Welcome to Heart Corner: Innovations in Cardiovascular Science, where we explore the latest advancements and breakthroughs in the field of cardiovascular science. This podcast discusses cutting-edge research, emerging therapies, and transformative technologies shaping the future of cardiovascular care. Join us as we discuss a wide range of topics, from groundbreaking studies on heart disease prevention and treatment to in-depth conversations on conditions like heart failure, arrhythmias, and cardiometabolic health.

Информация

  • Автор
    Abdulla A. Damluji, MD, PhD
  • Годы выхода
    2 тыс.
  • Выпуски
    17
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © Abdulla A. Damluji, MD, PhD
  • Сайт подкаста
    Heart Corner: Innovations in Cardiovascular Science

Вам может также понравиться

Чтобы прослушивать выпуски с ненормативным контентом, войдите в систему.

Следите за новостями подкаста

Войдите в систему или зарегистрируйтесь, чтобы следить за подкастами, сохранять выпуски и получать последние обновления.
Выберите страну или регион

Африка, Ближний Восток и Индия

Азиатско-Тихоокеанский регион

Европа

Латинская Америка и страны Карибского бассейна

США и Канада